Study Title
AAML1831: A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Protocol ID
AAML1831
Condition/s
Acute Myeloid Leukemia
Diagnosis Stage
Newly diagnosed
Location
QLD
Sponsor
Children's Oncology Group
Links
Trial Status
Open
Sites
Queensland Children's Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
up to 21 Years
International registry ID's
NCT04293562
| Study Title | AAML1831: A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations |
|---|---|
| Protocol ID | AAML1831 |
| Disease (Sub Disease) | Acute Myeloid Leukemia |
| Diagnosis Stage | Newly diagnosed |
| Location | QLD |
| Sponsor | Children's Oncology Group/ |
| Links | https://clinicaltrials.gov/study/NCT04293562 |
| Trial Status | Open |
| Trial Open Date | 21/07/2020 |
| Sites | Queensland Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | up to 21 Years |
| International registry ID's | NCT04293562 |